Journal of Thoracic Oncology, 1556-0864

Journal

Related Publications
  1. Brain metastases (BM) development after chemoradiation (CRT) for stage HI non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?

    Hendriks, L., Brouns, A., Amini, M., Uyterlinde, W., Wijsman, R., Biesma, B., Stigt, J., De Ruysscher, D., van den Heuvel, M. & Dingemans, A. -M., Apr-2016, In : Journal of Thoracic Oncology. 11, 4, p. S106-S106 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  2. Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center

    Ali, A., Tamber, G. S., Camilleri-Broet, S., Cohen, V., Spicer, J., Wang, H., Chong, G., Munazzit, M., Rousseau, C., Sateren, W., Fernandez, M., Kasymjanova, G., Owen, S., Spatz, A., Van Kempen, L. & Agulnik, J., Oct-2018, In : Journal of Thoracic Oncology. 13, 10, p. S666-S666 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  3. Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study

    Heist, R. S., Garon, E. B., Tan, D. S. W., Groen, H. J. M., Seto, T., Smit, E. F., Nwana, N., Fairchild, L., Balbin, A., Yan, M., Wang, I., Giovannini, M., Sankaran, B. & Wolf, J., Feb-2020, In : Journal of Thoracic Oncology. 15, 2, p. S30-S31 2 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  4. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

    Huber, R. M., Hansen, K. H., Paz-Ares Rodríguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., Tiseo, M., Smit, E. F., Kim, D-W., Gettinger, S. N., Hochmair, M. J., Kim, S-W., Langer, C. J., Ahn, M-J., Kim, E. S., Kerstein, D., Groen, H. J. M. & Camidge, D. R., Mar-2020, In : Journal of Thoracic Oncology. 15, 3, p. 404-415 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

    Barlesi, F., Audigier-Valette, C., Felip, E., Ciuleanu, T., Jao, K., Rijavec, E., Urban, L., Aucoin, J., Zannori, C., Vermaelen, K., Frontera, O. A., Ready, N., Fontecedro, A. C., Linardou, H., Poddubskaya, E., Fischer, J., Iordan, I., Groen, H., Pillai, R., Li, S., Fiore, J., Chang, H., Acevedo, A. & Paz-Ares, L., Oct-2019, In : Journal of Thoracic Oncology. 14, 10, p. S214-S215 2 p.

    Research output: Contribution to journalMeeting AbstractAcademic

View all (69) »

ID: 2469901